At a glance
ClinicalIndex Comparison RecordN/ACompleted· 41 enrolled
Drug / intervention
Zyvox (linezolid)drug
Likely dose
Zyvox (linezolid) 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan)
In Brief
An observational study evaluating Zyvox (linezolid) for Vancomycin Resistance Enterococcus Faecium. Completed, enrolled 41 participants.
Detailed Summary
To collect the efficacy and safety information in subjects who have been treated with Zyvox (linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate use in daily practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedOct 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedOct 20, 2010
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.7 years ago
Interventions
Zyvox (linezolid)drug
Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.